How newly unemployed over-50s can start-up again – The Guardian

Max Wallace, a former professional boxer with an interest in art, wants to set up his own wellbeing centre. Sunil Jindal plans to set up a Mumsnet for older men while Sharon Thomas has a business model to monetise her mini artwork greetings cards.

But these entrepreneurs face one problem: theyre over 50 and although the state pension age rises to 66 on Tuesday, 54-year-old Jindal said they already risk being perceived to be over the hill by everyone from banks to, occasionally, themselves.

Ive had a very successful career in computer science, reaching director level, but when my last employer and I went our separate ways in July, I found it a real shock to be back in the job market, Jindal said.

Im applying for jobs but Im planning my own business too because I cant help asking myself: Will I find something at my age? Theres so much stigma around older people out there and I find I doubt myself too; can I reposition my USP at my age, deal with the technology, sustain the energy? he added.

Wallace has no shortage of energy, having set up a community interest company called Health Defence which offers fitness programmes, aimed at combatting ill health in the community. He now hopes to open a micro wellbeing centre in Hammersmith, west London, where people can access his boxing/kickboxing fitness programme, along with healthy eating workshops, massages and free health checks.

Around 377,000 older workers one in 10 male, and eight in 10 female workers in their 50s and 60s face a significant risk of losing their jobs as the governments furlough scheme is wound down this month, according to the Centre for Ageing Better and the Learning and Work Institute.

That is in addition to the recent doubling in the number of people over-50s already claiming unemployment-related benefits between March and May. According to an analysis of official data by Rest Less, a jobs, money and lifestyle site for the over-50s, numbers rose from 304,000 in March to 588,000 in June. This means that more over-50s are claiming universal credit than under-25s.

Additional analysis of Department for Work and Pensions data by the Centre for Ageing Better found that over-50s are less likely to bounce back from unemployment than any other age group: just 35% who lose their job return to work quickly, with 29% remaining unemployed for more than 12 months.

These statistics are causing concern among experts. Last week, the International Longevity Centre UK (ILC), the UKs specialist thinktank on the impact of longevity on society, urged the government to introduce a scheme akin to Kickstart but focused on the needs of older workers.

The long-term growth in employment of those aged over 50 has stalled, with too many people forced out of the workforce too early, said David Sinclair, ILC director. These older workers contribute to economic growth but are likely to find it much more difficult than other ages to get themselves another job.

Andy Briggs, group CEO at Phoenix Group and Government Business Champion for Older Workers, agreed. We know that if you become unemployed over the age of 50 you are less likely than any other group to get another job.

Suzanne Noble, who co-founded Advantages of Age with Rose Rouse, said this is a problem for which there are limited solutions. Noble, who has co-founded the Startup School for Seniors which launched on Monday, said a move into self-employment is one of the most positive and realistic choices available.

Lack of confidence is the key challenge for this age group, said Noble, who has also launched Silver Sharers, a website that matches homeowners aged 50-plus with lodgers of any age. We know, from previous work done with over-50s, that when an older person loses their job it can take a real toll on their mental health.

If youve been working for decades in a career, the expectation is that will deliver you into a comfortable retirement, she added. When that outcome is taken away from you, it can be crushing. Many feel that their work experience no longer has any value and that theres nowhere for them in the modern workplace.

But thats simply not the case, said Noble. Experience is one of the most important USPs of this group, so ignore it at your peril, she said. We have a more relaxed attitude to other people and their opinion about us: the No Fucks Given-movement stole the idea from their elders and betters.

The statistics show the value of that experience: businesses started by those aged over 45 are more likely to be successful than those created by those aged 18-25 years.

Mark Elliott, Nobles co-founder of the free, eight-week online Startup School for Seniors whose 60 participants are aged between 50 to 75 pointed out that modern technology is easier to use than it ever has been. If Covid-19 has taught us nothing else, its that many more older people have become digitally savvy through using Zoom and other video conferencing software, he said.

Theres no reason to assume that someone 50-plus hasnt got the aim or ambition of building a fast-scaling tech business but older entrepreneurs need to be realistic, he said.

Theyre not going to suddenly become Richard Branson but then, would they want to? he asked. On top of what opportunities there are, is the extra question, what sort of opportunities are people this age usually looking for?

With one in five people over 50 being informal carers, flexibility is key, said Elliott. Added to which, older people are often seeking a job that provides them with satisfaction as well as a pay cheque. At this stage in our lives, we need to build a business that we want to work in ourselves. Thats exciting.

Originally posted here:
How newly unemployed over-50s can start-up again - The Guardian

100 years old will be the new 60 | Health & Wellness – CL Charlotte

For the first time in history, leading scientists and entrepreneurs believe theres a way to slow aging and maybe even reverseit.

The latest research on longevity suggests there is no reason that people born today cant live to at least 120 years old... perhaps even to 150 and beyond.

How would you change your life if you could live to 120 years old and remain healthy?

What would you do differently today?

Last week we explored the Longevity Mindset. Today and next week, Ill do a quick review of the latest advancements toward rewiring the biology of aging.

Every year, I take a group of my Abundance 360 Members on a Platinum Longevity Trip to meet with the cutting-edge researchers and companies. Following are some of the companies and technologies we observed that have the potential to increase your healthspan the amount of time you have to live a healthy and functional life, avoiding expensive end-of-life care.

Todays blog will be part one of a two-part series covering these developments.

Lets dive in

Over the past two decades, the cost of sequencing the human genome has dropped 100,000-fold: from $100 million per genome, to below $1,000 per genome (current estimates are as low as $300).

Genome sequencing can uncover disease susceptibilities years before symptoms present, allowing for personalized preventative care to begin sooner than ever before.

For example, the Cancer Genome Atlas Program at the NIH is currently using gene sequencing to decode the genetic underpinnings of 30 cancer types.

Perhaps the most impactful potential of low-cost genome sequencing is its ability to be used in what is called a liquid biopsy the ability to find free-flowing cancer DNA in your bloodstream that might indicate the existence of an undetected cancer in your body. And, as we know, finding cancer at stage-zero or stage-one is the key to survival.

There are two major companies we visited with during our Platinum Longevity Trip:

Cancer detection company GRAILanalyzes the mutated, fractionated DNA and RNA from cancer cells in your blood (from a simple blood draw) to diagnose over 50 cancer types in early stages. GRAIL recently received an $8 billion buy-out offer from biotech giant Illumina.

Freenometakes a similar approach to early cancer diagnosis from a real-time blood draw (called a liquid biopsy), initially focused on colon cancer. Freenomes multiomics platform analyzes fragments of DNA, RNA, and protein from the cancer and from the host response. This form of precision medicine bridges early detection and early intervention to boost human healthspan.

One of the most powerful technologies now available in the fight for longevity is called gene therapy a technology theorized in the 1980s that has taken almost 40 years to mature. Gene therapy allows scientists to use a vector (typically an Adeno Associated Virus) to carry a desired gene to a set of desired cells in an organism. Want a specific gene put into retinal cells, or bone marrow, or neurons? No problem, there's a gene therapy approach for that.

A new biotech start-up called Gordian Biotechnologyis using the convergence of gene therapy and single cell sequencing to run hundreds of thousands of independent experiments in a single animal to determine the therapeutic effects of specific gene additions on specific cells of interest. Because aging is such a multifactorial process, this approach can run thousands of parallel experiments to tackle the many complexities of age-related diseases simultaneously.

Next week, well learn about a company called Rejuvenate Bio, and an extraordinary researcher named Dr. David Sinclair who is using gene therapy to potentially rejuvenate animals with the ultimate goal of age reversal in humans.

In addition to Gene Therapy, the other incredible tool in our longevity research arsenal is CRISPR.

You may know CRISPR as the molecular scissors that can edit genes think CTRL X (cut) and CTRL V (paste). But beyond cutting and pasting, CRISPR can also be used to help find and identify a sequence of DNA in your cell, sort of a CTRL F functionality. This discovery is so important and transformative that the Nobel Prize was just awarded this month to Dr. Jennifer Doudna of Gladstone Institutes for its discovery.

Here are several other exciting CRISPR developments:

Gladstone-UCSF Institute of Genomic Immunologyis using CRISPR to edit the T-cells of the immune system that play critical roles in cancer, infection, and autoimmunity. CRISPR can delete mutated genes or add new DNA to reprogram the T-cells. This personalized approach takes advantage of the bodys own immune system to tackle complex diseases.

Rather than snipping and replacing genes, Mammoth Bioscienceshas programmed CRISPR proteins to locate and cleave target genes, acting as molecular shredders. The cleaved gene serves as a molecular readout if the target is successfully bound, enabling CRISPR to serve as a diagnostic tool. Additionally, the companys novel CRISPR proteins (cas14, casV) exist in the micro and nano scales, opening the door for new delivery systems at smaller scales than ever before.

With the recent breakthroughs in CRISPR and Gene Therapy technologies, a variety of strategies for reversing disease have been tried. Yet countlessexperiments remain, and thats where AI can help.

The explosion of novel imaging, sensing, and sequencing tools has unleashed an abundance of patient data.

But bringing together this information across millions of patients to form actionable insights can only be achieved with Artificial Intelligence.

One of the leading companies in this area is Insilico Medicine, which is leveraging AI in its end-to-end drug pipeline, extending healthy longevity through drug discovery and aging research.

In their comprehensive drug discovery engine, Insilico uses millions of samples and multiple data types to A) discover signatures of diseases, and B) identify the most promising targets for billions of molecules. These molecules either already exist or can be generated de novo with the desired set of parameters.

Insilico uses an AI technique called generative adversarial networks (GANs) to imagine novel molecular structures. With reinforcement learning, Insilicos system lets you generate a molecule with any of up to 20 different properties to hit a specified target.

Thanks to converging breakthroughs in machine learning, drug discovery and molecular biology, companies like Insilico can now do with 50 people what the pharmaceutical industry can barely do with an army of 5,000.

Another extraordinary company on the Longevity Platinum Trip was a company out of the Buck Institute called Edifice Health, which has developed the ability to determine your inflammatory age using advanced AI to score biomarkers of immune health. Inflammation is a leading contributor to most chronic illnesses, and greater awareness of this symptom will enhance preventative care. Even more important than measuring inflammatory age, Edifice Health is screening thousands of molecules to determine which can quell such inflammation.

An additional company out of the Buck Institute is Gerostate Alpha, a pharmaceutical company that is using large-scale AI to test millions of compounds for their ability to extend the life of a worm-like creature called the nematode. Once they get a hit in nematodes (rather short-lived creatures), they will then test the molecules in mice and eventually in humans. The company is testing millions of compounds in parallel, hoping to literally discover the pharmaceutical fountain of youth.

In next weeks blog, well continue to review other exciting companies on the cutting-edge of longevity science, diving more into gene therapy, senolytic medicines, vaccines, and stem cells.

If tracking the latest breakthroughs in longevity is something you desire If developing a Longevity Mindset is important to you, then consider joining my Abundance 360Mastermind.

Every year, my team and I select a group of 360 entrepreneurs and CEOs to coach over the course of a year-long program. A360 starts each January with a live event and continues every two months with Implementation Workshops, in which I personally coach members in small groups over Zoom. (In January 2021, you have a choice of live in-person or virtual participation. See the A360 website for more info.)

My mission is to help A360 members identify their massively transformative purpose, select their moonshot, and hone an Abundance, Exponential, and Longevity Mindset. Together we will actively select and reinforce your preferred mindsets.

To learn more and apply, visit abundance360.com

Read the original post:
100 years old will be the new 60 | Health & Wellness - CL Charlotte

David Sinclair | The Sinclair Lab

David A. Sinclair, Ph.D., A.O. is a Professor in the Department of Genetics and co-Director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School. He is best known for his work on understanding why we age and how to slow its effects. He obtained his Ph.D. in Molecular Genetics at the University of New South Wales, Sydney in 1995. He worked as a postdoctoral researcher at M.I.T. with Dr. Leonard Guarente where he co discovered a cause of aging for yeast as well as the role of Sir2 in epigenetic changes driven by genome instability. In 1999 he was recruited to Harvard Medical School where he has been teaching aging biology and translational medicine for aging for the past 16 years. His research has been primarily focused on the sirtuins, protein-modifying enzymes that respond to changing NAD+ levels and to caloric restriction (CR) with associated interests in chromatin, energy metabolism, mitochondria, learning and memory, neurodegeneration, and cancer. The Sinclair lab was the first one to identify a role for NAD+ biosynthesis in regulation of lifespan and first showed that sirtuins are involved in CR in mammals. They first identified small molecules that activate SIRT1 such as resveratrol and studied how they improve metabolic function using a combination of genetic, enzymological, biophysical and pharmacological approaches. They recently showed that natural and synthetic activators require SIRT1 to mediate the in vivo effects in muscle and identified a structured activation domain. They demonstrated that miscommunication between the mitochondrial and nuclear genomes is a cause of age-related physiological decline and that relocalization of chromatin factors in response to DNA breaks may be a cause of aging.

Dr. Sinclair is co-founder of several biotechnology companies (Sirtris, Ovascience, Genocea, Cohbar, MetroBiotech, ArcBio, Liberty Biosecurity) and is on the boards of several others. He is also co-founder and co-chief editor of the journal Aging. His work is featured in five books, two documentary movies, 60 Minutes, Morgan Freemans Through the Wormhole and other media. He is an inventor on 35 patents and has received more than 25 awards and honors including the CSL Prize, The Australian Commonwealth Prize, Thompson Prize, Helen Hay Whitney Postdoctoral Award, Charles Hood Fellowship, Leukemia Society Fellowship, Ludwig Scholarship, Harvard-Armenise Fellowship, American Association for Aging Research Fellowship, Nathan Shock Award from the National Institutes of Health, Ellison Medical Foundation Junior and Senior Scholar Awards, Merck Prize, Genzyme Outstanding Achievement in Biomedical Science Award, Bio-Innovator Award, David Murdock-Dole Lectureship, Fisher Honorary Lectureship, Les Lazarus Lectureship, Australian Medical Research Medal, The Frontiers in Aging and Regeneration Award, Top 100 Australian Innovators, and TIME magazines list of the 100 most influential people in the world.

David A. Sinclairs Past and Present Advisory roles, Board Positions, Funding Sources, Licensed Inventions, Investments, Funding, and Invited Talks.

Go here to see the original:
David Sinclair | The Sinclair Lab

DS4 to rock Morden live at The Sound Lounge – Your Local Guardian

After their shows were cancelled due to the pandemic, DS4 will return to music by headlining at The Sound Lounge this weekend.

Rock band DS4 is set to headline at the grassroots music venue in Morden on Saturday September 25.

The audience at the Sound Lounge can expect a "rock and roll show with a vintage touch" between 7.00 pm to 9.30 pm.

Singer, songwriter and guitarist David Sinclair,says the performance is the groups lifeline.

DS4 came together when David Sinclair hooked up with guitarist Geoff Peel, a sage of the London blues circuit.

Together with Jos Mendoza, ex bass player Jack Sinclair and a cast of special guests, they recorded the album 4 in 2015. Gigging around London venues, including The Borderline, 100 Club and Half Moon Putney, and festivals such as Cornbury and North Wales Blues and Soul Fest, the DS4 has built up a dedicated following.

And won glowing testimonials for a show full of good time rock and roll energy, stirring personal blues ballads and wry narrative wit.The band featuring drummer Rory, has sold-out gigs at the Crawdaddy Club in Richmond, Dustys Blues Club in High Wycombe, Portobello Live and Gunnersbury Triangle Club.Their latest album Sweet Georgina has received ecstatic reviews, with their track 'The Rolling People' featuring on the CD covermount of Classic Rock magazine last year.

With years of entertaining and months of having to stay inside, the band are "over the moon" to be back in front of an audience.

A spokesperson for DS4 said: "The Sound Lounge can look forward to a glorious show featuring original songs from our first five albums.

"Mixed with classic covers of songs by Lou Reed, Chuck Berry and the Red Hot Chili Peppers.

"Live performances are the oxygen that keeps a band like us alive.

Its been a long time to manage without it, and this show is a lifeline for us.

"Zoom and Spotify are all very well.

"But we just cant wait to make contact with hearts and minds in the outside world again.

For ticket information visit http://www.thesoundlounge.org.uk/whats-on

See the original post:
DS4 to rock Morden live at The Sound Lounge - Your Local Guardian

Brexit casts doubt over UK pension rights – Interactive Investor

Future retirees are facing uncertainty over the level of state pension they will receive if they move abroad and could miss out on around 140,000 of income once the Brexit transitional period ends, Aegon claims.

The pension company is warning that the outcome of Brexit negotiations could have a huge impact on the retirement prospects of UK citizens who plan to move to and retire in the European Union (EU) or Switzerland.

Currently, those who are already living in the EU before 31 December 2020 have been reassured that they will receive the same increases to UK state pensions as paid to those living in the UK.

This is based on the triple lock, which guarantees the state pension will rise by the highest of earnings growth, price inflation or 2.5% each year.

However, aside from those who move to Ireland, there has been no guarantee from the UK on the level of the state pension for those retiring and living in other countries.

Steven Cameron, pensions director at Aegon, says: The outcome of last-minute Brexit negotiations could have a huge impact on those who may be planning to retire abroad to another EU country.

With many people living 20 or more years after state pension age, any form of inflation proofing is highly valuable, with the triple lock particularly so.

An inflation linked state pension of 175.20 a week is worth 336,500 whereas one that doesnt increase is worth 191,000 which is 145,500 less.

Cameron adds that while the treatment of state pensions may not be top of the agenda for last minute Brexit negotiations, he warns decisions in these areas could make a huge difference to those planning to move abroad in future for their retirement years.

David Sinclair, director of thinktank the International Longevity Centre, says: For some older people, the state pension provides a significant part of their retirement income.

These people in particular will want to be confident that they can afford their retirement aspirations irrespective of whether they stay in the UK or move abroad.Older people who want to move abroad need to be confident that value of their savings alongside their pension will be adequate.

Sinclair adds that retirees will need to make their wealth last 20-plus years and says this uncertainty is unhelpful for those who want to plan for the long term.

These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.

Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.

Read more from the original source:
Brexit casts doubt over UK pension rights - Interactive Investor

Cancer. How close are we to winning the war? – Switzer

When I started my medical degree in the 1970s, a diagnosis of cancer was typically a death sentence. Occasionally, if cancer was detected early, there was some hope for surgical resection. The radiotherapy and chemotherapy used back in those days was rather primitive and certainly often extremely toxic to the body.

Now in the year 2020, despite significant emphasis being appropriately placed on improved therapies and vaccines for COVID-19, the medical world is closing in on a cure for cancer. Over the past decade, the widespread use of immunotherapy and the somewhat newer CAR-T therapies & their spinoffs have revolutionised the treatments of many cancers including haematologic cancers, such as leukaemia and lymphoma but also the common solid tumours such as breast, prostate, colon, lung and melanoma, to name a few.

One of the issues with cancers is that they form a shield around individual tumour cells making them almost invisible to the immune system. Many of the newer immunotherapies help break down the shield, allowing the bodys own immune system to attack the tumour cells.

One of the best group of tumour killing cells in the immune system are T cells known as Tumour Infiltrating Lymphocytes (TILs). Although these are probably the best soldiers of the immune system, once they enter the battlefield of the tumour micro-environment they are disabled by many of the stressors present in this situation. All cells, whether they be our own naturally occurring cells or those of tumours that have formed in our body, require a supply of nutrients and oxygen to function correctly.

Thus, when a TIL enters a tumour to do its work, it is competing with the tumour for local nutrients and oxygen. The tumour being extremely greedy steals these nutrients leading to a reduction in the function of a component of all cells known as the mitochondria. Mitochondria are the fuel supply of the cell creating energy for the cell, allowing it to do its work and exist. If we deprive the mitochondria of nutrients, the mitochondria are converted into a sluggish state known as terminal exhaustion. Also, when the T cells mitochondria are starting to age, there is a natural process that breaks down the cells and replaces them with younger, healthier T cells to continue the job of trying to destroy any tumours that are present.

The function of any living cell, including T cells and tumour cells, is to survive. Cancer cells create particular antigens which stimulate a protein known as PD-1, which suppresses the T-cell response. Thus, when you have cancer, there is this constant battle being waged inside your body between your own immune system and the tumour.

Now for the good news. Scientists from the US have discovered that a commonly used supplement for anti-ageing known as NAD-riboside enhances mitochondrial function in these failing T cells and allows them to recharge themselves to enhance their attack against tumours. When NAD-riboside was added to specific immunotherapy drugs, this significantly inhibited the growth of a variety of tumours in mice.

Professor David Sinclair from Harvard University has pioneered the use of NAD-riboside for anti-ageing demonstrating that this is a safe and effective supplement, prolonging the life of laboratory animals by 20%. Prof Sinclair has also demonstrated the same anti-ageing markers in human beings. There now appears to be another feather in the cap for this safe and seemingly effective supplement, which may become standard care to be added to all new cancer therapies.

A word of caution in that this has not been trialled in humans as additional therapy but, many people, including myself, already take NAD-riboside or a related supplement e.g. NMN; NAD plus, as a potential anti-ageing therapy. I have been saying for a number of years that vitamin B3 and its variety of analogues such as NAD-riboside are a vital part of good health. This is yet more evidence to support these claims. Although we have not achieved a cure for cancer in 2020, we are certainly edging closer.

Go here to read the rest:
Cancer. How close are we to winning the war? - Switzer

Where Sabrina the Teenage Witch cast are now – hit TV shows and unrecognisable star – Mirror Online

Forget the point black hat and long nose, there was only one witch every 90s teenager wanted to be - Sabrina.

With one quick point, she could have the perfect outfit, fix her homework or embarrass her school enemy.

Sabrina the Teenage Witch first aired in 1996 and ran for seven years, following Sabrina Spellman, her cat Salem, aunts Zelda and Hilda, on/off flame Harvey and many more memorable characters.

But what became of the family, the teachers and the boys after the show came to an end in 2003?

Let's take a trip through the closet to the Other Realm and find out what they've all been up to...

As the star of the show, it's not surprising that Melissa Joan Hart enjoyed a successful TV career post Sabrina.

The former Clarissa Explains It All actress became a household name thanks to her magical role.

After Sabrina wrapped in 2003 Melissa starred in Nine Dead and Robot Chicken and starred in Melissa and Joey, which ran for five years.

Over the years she's spoken openly about her past drug issues, but the mum-of-three has been enjoying a new lease of life after losing weight and loving her time with hubby Mark Wilkerson.

On her Twitter, she says her "favourite role" has been being mum to her boys Mason, Brady and Tucker.

Whimsical Aunt Hilda was a definite favourite on the show - and her love story with Will the train conductor was heartbreaking stuff.

Actress Caroline Rhea took on a lesser role when Sabrina went to college, so the actress had time to host a talk show.

She went on to star in Christmas with the Kranks, The Perfect Man and Love N' Dancing.

She also voiced Linda Flynn-Fletcher on Disney's animated comedy Phineas and Ferb for more than 100 episodes

Caroline has also starred in a series of TV movies including A Christmas in Tennessee and she's currently filming Sydney to the Max.

The other - slightly more sensible - half of the sibling duo, we all remember Aunt Zelda well.

Beth had already starred in The Bonfire of the Vanitie, Hearts Afire and The 5 Mrs Buchanans before starring as Zelda.

As well as parts on Under the Dome and Lost, Beth Broderick has taken on stage roles.

She was reunited with Melissa Joan Hart in 2014 when she made two guest appearances as Dr. Ellen Radier in Melissa & Joey.

She also went on to star in Timber Falls and episodes of Cold Case and Castle.

Beth has two things in the pipeline, Something About Her and Law of Attraction.

Harvey, Harvey, Harvey. How could we forget.

Now a musician, Nate surprised fans when she shared a photo of himself in 2015.

Gone is the windswept, chiselled and clean-shaven look that captured Sabrina Spellman's heart, now sporting a pair of glasses and slight stubble - and not quite as much hair.

He hasn't given up acting altogether, having gone on to star in Lovely & Amazing, Survival Island and episodes of The Tony Danza Show, Fantasy Island and Touched by An Angel.

However, he's had to take up other jobs to pay the bills.

Back in 2018 he tweeted: "Im currently a maintenance man, a janitor, a carpenter, and do whatever random jobs I can get to pay the bills."

He also enjoys improv and writes songs.

The bully of the show, Libby was a thorn in Sabrina's side until her exit in season four.

Since leaving the show, Jenna Leigh Green has enjoyed a successful career, even keeping it in the world of magic with a role in Wicked as it toured North America.

The star also lent her voice to Extreme Ghostbusters and starred in Dharma & Greg, ER, Cold Case, You Again, Quantico and Bones.

She also took to the stage in Tonya and Nancy: A Rock Opera.

Jenny's time on the show was short lived, but her dreams of other worlds hidden behind closets led to her accidentally going through the Spellman's secret entrance.

After she left the sitcom after just one season, she went on to make appearances on the likes of The Outer Limits and Da Vinci's Inquest.

She starred in Cold Squad in 2005 and then in Le coeur a ses raisons in 2006, which seems to have been her final acting appearance.

Michelle moved to Europe, which may explain why there's not much on record after 2006.

But it sounds like she's tried her hand at lots of different things, as her Twitter bio reads: |Mom. Cuelr. Tech. Music. Design. Fashion. Film, TV & Theater. J'actress of all trades."

Little known fact about Michelle - she starred in the 1996 Sabrina movie as Marnie Littlefield.

Valerie Birkhead was Sabrina and Harvey's best friend at high school, and she remained on the show until season four.

After leaving, she starred in the likes of Bring It On, The Other Guys and both Horrible Bosses and its sequel.

Lindsay also pops up in The West Wing, Grosses Pointe and The Stones.

She can also be seen as Emily in Matthew Perry's sitcom The Odd Couple.

Detention! Not really, but if Mr Kraft was here, it'd happen at a drop of a hat.

Veteran actor Martin Mull was the man behind the role, and he has enjoyed a career spanning six decades - including the likes of Clue, Roseanne and Mary Hartman, Mary Hartman.

He appeared as George Perry on Community, and has also been seen as Russell the pharmacist on Two and a Half Men. The star also starred in Arrested Development, Dads, Veep and Brooklyn Nine-Nine.

OK, we're definitely #TeamHarvey, but Josh gave him a run for his money at the coffee shop.

David Lascher - who previously appeared in Nickelodeon series Hey Dude - took on the role, although his short romance with Sabrina only really came to fruition in season six.

Like Beth, he was reunited with Melissa Joan Hart during Melissa & Joey when he made a guest appearance as Charlie. He's also starred in Blossom with Joey Lawrence, who played Joey in the show.

Sarcastic and hell-bent on global domination, we couldn't get through this without bringing up the Spellman family pet.

He was voiced by Nick Bakay, who was also a writer on the show and its cartoon spin-off Sabrina, the Animated Series.

Amongst his credits are the likes of The Queen of Queens, Paul Blart: Mall Cop (and it's upcoming sequel) and The Adventures of Baxter and McGuire.

He also popped up in In Living Color and Coach as well as The Simspons.

He lives in the Hollywood Hills with his wife, Robin, who he married in 1994.

Soleil was Sabrina's roommate Roxie King. The former child star rose to fame in Punky Brewster, and following her role on Sabrina voiced The Proud Family, Bratz, Planet Sheen and Robot Chicken.

She also appeared in an episode of Friends, in which she dated Joey but kept hitting him.

In 2007 she launched The Little Seed an environmentally-conscious children's boutique but it closed in 2012 and now runs as an online business.

She's also released a number of books, including Happy Chaos: From Punky to Parenting and My Perfectly Imperfect Adventures in Between and party-planning guideLet's Get This Party Started.

Sabrina's other roommate Morgan was played by Elisa Donovan, who joined the show after starring in Clueless as Amber.

She's gone on to appear in Judging Amy, NCIS, The Lake and In Gayle We Trust.

Like many of her other Sabrina co-stars, she's also had a guest role on Melissa & Joey.

Alimi appeared as the Quizmaster Albert in Sabrina The Teenage Witch.

He's known for playing FBI agent David Sinclair on Numb3rs and he's starred in Queen Sugar, Lucifer, Criminal Minds and The Catch.

His most recent big role is as Marcel Dumas on Queen of the South.

Alimi, who lives in New York, is married and has two children.

Read more:
Where Sabrina the Teenage Witch cast are now - hit TV shows and unrecognisable star - Mirror Online

We all suffer when COVID-19 locks the elderly out of societal participation – The Investment Observer

Keep people healthy to keep countries wealthy laments David Sinclair, Director of the International Longevity Centre UK. According to the think-tank leader, we are chronically guilty of under-appreciating our elderly peers, and their importance to both society and the economy.

Aside from the our sentimental attachments and the expertise our betters might offer, Mr Sinclair states that 54p in every pound is spent by people aged 50 and over, with this group offering a potential GDP boost of 2% per year by 2040. Across the G20, he says, the picture is much the same.

Thats why he thinks its crucial that G20 Health and Finance Ministers meet on Thursday. He says that COVID-19 has shown us just how true the health equals wealth adage is, with countries across the world being plunged into one of the hardest-hitting global recessions in memory.

The key to recovery, Mr Sinclair claims, is an appreciation not only of how important a role elderly citizens play in the modern world, but in turn an effort to better engageolder workers, older consumers, older volunteers and older carers, who contribute immensely to the global economy.

Instead, Mr Sinclair states that:

[] during COVID-19, older people have been disproportionately locked out of working, spending, caring and volunteering. And we know that health is a key barrier to maximising the potential of an ageing society.

Our research has shown that across better off countries, in 2017 alone, 27.1 million years were lived with largely preventable age-related diseases, leading to more than $600 billion worth of lost productivity every year. In the UK alone, about a million people aged 50-64 are forced out of work as a result of health and care needs or caring responsibilities.

If we are to deliver a potential longevity dividend, in the post-pandemic recovery and beyond, we need to ensure we are supporting people to not just live longer, but also healthier lives and promoting preventative health interventions right across the life course.

This, Sinclair argues, means that we need to gear both our post-pandemic recovery and our future, ageing society, towards keeping people healthier for longer. He says the costs of failing to adapt to both the needs of our increasing, elderly populace, and ignoring their potential as productive and active participants in society and the economy, are simply too high to ignore.

So where does this leave us? Well, avoiding the divisive and played out old versus young blame game, any post-pandemic new normal needs to find a way of protecting our elderly peers, while still engaging them in social and economic interactions. Some suggest that over time youngsters might return to some semblance of life before COVID, while the vulnerable remain shielded.

What we must avoid, however, is shielded becoming synonymous with excluded. For those that cannot expose themselves to the general public, part of the solution might involve bringing the world to the elderly, via technology. With greater tech education and utilisation, our elderly peers will not only be able to socialise, but participate in non-physical work.

Though, while tech might enable our ageing population to have a more active role in future society, it should not be viewed as the panacea to our current predicament. Like it or not, keeping our elderly healthy and safe requires all of us being prudent and careful. This ought to take place as part of a wider mindset shift, from seeing our wiser peers not just as burdens, but as potentially invaluable assets that we have to look after.

Continue reading here:
We all suffer when COVID-19 locks the elderly out of societal participation - The Investment Observer

Immetas Therapeutics Announces Series A Financing to Advance Research on Inflammation Pathways in Aging and Develop Therapeutics for Cancer and…

EAST HANOVER, N.J.--(BUSINESS WIRE)--Immetas Therapeutics today announced it has raised a Series A financing of $11 million to advance research on inflammation pathways in aging and the development of novel, immune modulating treatments for cancer and inflammatory disease. Morningside Ventures was the sole investor in the financing round.

Morningsides investment is a significant endorsement of our approach to targeting inflammation pathways in aging and our clinical evidence-based discovery strategy, said J. Gene Wang, MD, PhD, co-founder and CEO. Emerging research that molecular pathways driving both aging and age-related diseases converge around chronic, low grade inflammation is creating a new set of opportunities to treat cancer and other serious diseases. Immetas is well positioned to capitalize on these new advances.

Dr. Wang added, Our approach prioritizes clinical evidence and a deep interrogation of disease mechanisms to guide drug discovery. This strategy is designed to reduce development risk resulting from the translational gap between laboratory findings and patients and ensure the development of superior and well-differentiated drugs.

Dr. Wang co-founded Immetas after a 20-year career at large pharmaceutical companies, including Merck, Abbott, GSK and Novartis, where he played integral roles in the successful development of major drugs, including Humira (adalimumab), Varubi (rolapitant), Zolinza (vorinostat) and Gardasil (human papilloma virus vaccine), and led multiple programs from discovery to clinical proof-of-concept. Dr. Wang received his M.D. from Peking University Medical Center and Ph.D. in Immunobiology from Yale University, followed by medical residency training at Yale New Haven Hospital.

Immetas other co-founder, Dr. David Sinclair, is an internationally recognized scientist known for his research on genes and small molecules that delay aging, including Sirtuin genes, resveratrol and NAD precursors. He was among TIME magazines 50 Most Influential People in Healthcare in 2018. Dr. Sinclair is Professor of Genetics at Harvard Medical School and co-Director of the Paul F. Glenn Center for Biology of Aging Research at Harvard and he serves as a science advisor to the Company.

We have a shared vision that inflammation is the fundamental and ultimate process driving aging and age-related cancers and inflammatory diseases, said Dr. Sinclair. Our approach is distinct from others that have targeted conventional age-related pathways and to date have proved challenging.

The Company is building a pipeline of biologic and small molecule drugs internally and through collaborations. Immetas lead program is aimed at designing a series of bi-specific antibodies to regulate inflammation in the tumor microenvironment and overcome resistance to conventional immune checkpoint therapies.

In connection with the financing, Dr. Lu Huang, MD, MBA, Managing Director at Morningside Ventures, joined the Immetas board of directors. Since joining Morningside in 2003, Dr. Huang has led nearly three dozen healthcare / life science investments in China and the United States.

About Immetas TherapeuticsImmetas discovers and develops novel therapeutics that modulate the innate immune system to treat age-related cancers and inflammatory diseases. The companys approach is based on emerging evidence that chronic low-grade inflammation is a fundamental process governing aging and age-related diseases and anchored in clinical evidence to mitigate development risk. Immetas was founded by J. Gene Wang, MD, PhD, a veteran in discovery and translational drug development in immunology/ inflammation and oncology, and David Sinclair, PhD, Professor of Genetics at Harvard Medical School and a leader in the molecular mechanisms of aging. The lead program in the companys growing pipeline is focused on engineering bispecific antibodies to modulate inflammation in the tumor microenvironment and overcome resistance to the conventional immune checkpoint therapies. Learn more at http://www.immetas.com

Go here to read the rest:
Immetas Therapeutics Announces Series A Financing to Advance Research on Inflammation Pathways in Aging and Develop Therapeutics for Cancer and...

Woods, Waters, and Wildlife: Buy Licenses Now! | FCT News – Freestonecountytimesonline

by John Jefferson

Its hunting and fishing license renewal time. All current licenses expire on August 31. Next Monday at Midnight, youll need new ones unless you have a fishing license thats good for a year from the date you bought it.

That license can cause trouble; folks forget to renew at the odd time until a warden asks to see it. TPWD tried that for everybody in the 70s but it caused many to hunt and fish without a valid license out of forgetfulness. Its easier to stay legal when licenses expire on August 31.

Let the hot, dry, dog- days of August remind you. Or maybe count on the gully washer rainstorm alert you that often strikes just before dove season opens and scatters all the doves. But, if its an unusual year with no late August rain, I doubt if game wardens are going to accept that excuse. Even now, many are still ticketed for No License. More on that further down.

Licenses are a bargain. Hunting licenses start at $25, allowing you to hunt deer in season and small game, but not migratory birds. Like doves. For those, youll also need a state-issued Migratory bird endorsement on your license. Its $7 and available where licenses are sold. Other state endorsements you might need are Archery, Upland Game Bird, and Reptile and Amphibian (all are $7). If youre going to hunt ducks, youll need a $25 Federal migratory endorsement (duck stamp).

Fishing licenses are different. There are Freshwater Packages ($30), Saltwater Packages ($35), and All-Water Packages ($40). Each contains the appropriate endorsement(s).

Combination licenses (Combo $60) and Super Combo licenses ($68) allow both hunting and fishing. The Super Combo is the best bargain since it contains ALL endorsements and saves having to run back to buy an endorsement you suddenly discover you need.

Licensesare available through the TPWD website, by phone, or in person at more than 1,700 Texas retailers. Theyre also available from TPWD Law Enforcement offices, but only by appointment.

But people still forget. The excuses for not having a current license are varied and sometimes humorous. Former Law Enforcement Director Grahame Jones told of a man who said he thought he had a Lifetime License. Starting at $1,000, I think you would remember. Jones said some blamed their wives for not renewing it. Retired warden Jim Lindeman said quite a few claimed they brought the wrong wallet, after taking out every card in their billfold.

Major Alphonso Vielma spoke of a man who said he had always bought one and had never been checked, so he didnt buy one that year. Retired Colonel David Sinclair reported one hunter claimed he thought it was legal to use his sons deer tags since he was the sons legal guardian.

But my favorite was the other extreme. Retired Colonel Dexter Harris checked a fisherman who told him he had waited for him a long time. The man then produced a box containing licenses for the previous 20 years!

JJ

See the original post here:
Woods, Waters, and Wildlife: Buy Licenses Now! | FCT News - Freestonecountytimesonline

Editorial: Five Birdies That Signal Good Work | Opinion | thepilot.com – Southern Pines Pilot

Birdie, by Moore County Schools, for choosing transparency when it comes to how its handling the coronavirus in its schools.

Going back into schools for the first time since Gov. Roy Cooper closed them in March, it was a given that COVID-19 positive cases would turn up among students, teachers and staff at some point.

Rather than leave it to parents spreading stories on social media about cases at their respective schools, the district last week began publishing with daily updates a school-by-school spreadsheet of positive coronavirus cases. The spreadsheet is published on the school systems website, ncmcs.org, for all to see and compare.

Moore County is in the minority of school districts that have chosen to have some form of in-person attendance, so naturally everyone has been nervous about how that would go with the virus. So far, the system seems to be holding its integrity, and being open and transparent with the public about cases is a strong component of building faith.

Birdie, by the Moore County Health Department, for hosting a second Facebook Live discussion and question-and-answer session.

Between department Director Robert Wittmann and health educator Miriam King, the 40-minute session accomplished something that had been sorely lacking in the departments response: face-to-face communication.

The personal touch is important during this pandemic. Gov. Roy Cooper and health officials in several other counties have adopted that approach with regular in-person briefings, even when theres not a whole lot to share. Its a way for leaders to show themselves, speak for their actions, demonstrate to the public that they have a handle on matters.

This birdie could quickly become an eagle if the Health Department builds from here and increases the number of presentations and adds more opportunities for Wittmann and staff to address the public.

Birdie, by Karen Pence, Vice President Mike Pences wife, for her finger point last week at the Republican National Convention of Southern Pines own R. Riveter. Pence visited the company two years ago to highlight its mission to bring meaningful work to military spouses.

While traveling throughout our nation to educate military spouses about policy solutions President Trump has promoted, involving real, tangible progress in military spouse employment, I have been inspired to meet heroes like Lisa Bradley and Cameron Cruse, she said.

These military spouses decided to start their own business, R. Riveter, named after the Rosie the Riveter campaign used to recruit women workers during World War II. R. Riveter makes beautiful handbags designed and manufactured exclusively by military spouses. Many of those spouses live all over the country. They prepare and send their section of the bags to the company located in North Carolina, where the final product is assembled.

When you can be remembered two years later by someone like the Second Lady, you know youre doing something special.

Birdie, by Vito Gironda and all his extended family, for 40 years of serving this community. Vito and his brothers opened Vitos pizza on South East Broad Street in 1980 as their attempt at achieving the American dream. Theyve grown that business over the years to the point where they are virtually synonymous with Italian food in Southern Pines.

The restaurant business can be a fleeting one, so its rare when you find one still in business after 40 years. Thats a testament to the Girondas faith in the community and the flavorful food, not to mention Vitos massive annual summer garden.

Birdie, by David Sinclair, The Pilots recently departed managing editor. Sinclair spent the past 20 years at The Pilot, but his career covering Moore County for various news organizations stretches to 38 years. Yes, he started in high school.

The Moore County Board of Commissioners, who Sinclair covered for years, recently passed a resolution honoring him. You are better known in this community than we are, teased Board Chairman Frank Quis.

Sinclair approached every assignment with good humor, grace and integrity, and his Pinehurst sunset pictures are local legend.

Read the original post:
Editorial: Five Birdies That Signal Good Work | Opinion | thepilot.com - Southern Pines Pilot

A Harvard Geneticist Wants To Sell A Magical … – HuffPost

Renowned Harvard University geneticist David Sinclair recently made a startling assertion: Scientific data shows he has knocked more than two decades off his biological age.

Whats the 49-year-olds secret? He says his daily regimen includes ingesting a molecule his own research found improved the health and lengthened the life span of mice. Sinclair now boasts online that he has the lung capacity, cholesterol and blood pressure of a young adult and the heart rate of an athlete.

Despite his enthusiasm, published scientific research has not yet demonstrated the molecule works in humans as it does in mice. Sinclair, however, has a considerable financial stake in his claims being proven correct, and has lent his scientific prowess to commercializing possible life extension products such molecules known as NAD boosters.

His financial interests include being listed as an inventor on a patent licensed to Elysium Health, a supplement company that sells a NAD booster in pills for $60 a bottle. Hes also an investor in InsideTracker, the company that he says measured his age.

Discerning hype from reality in the longevity field has become tougher than ever as reputable scientists such as Sinclair and pre-eminent institutions like Harvard align themselves with promising but unproven interventions and at times promote and profit from them.

Fueling the excitement, investors pour billions of dollars into the field even as many of the products already on the market face fewer regulations and therefore a lower threshold of proof.

If you say youre a terrific scientist and you have a treatment for aging, it gets a lot of attention, said Jeffrey Flier, a former Harvard Medical School dean who has been critical of the hype. There is financial incentive and inducement to overpromise before all the research is in.

MELANIE MAXWELL FOR KHNMice frolic in Richard Millers pathology and geriatrics lab at the University of Michigan. Miller heads one of the three labs funded by NIH to test anti-aging substances on mice.

Elysium, co-founded in 2014 by a prominent MIT scientist to commercialize the molecule nicotinamide riboside, a type of NAD booster, highlights its exclusive licensing agreement with Harvard and the Mayo Clinic and Sinclairs role as an inventor. According to the companys press release, the agreement is aimed at supplements that slow aging and age-related diseases.

Further adding scientific gravitas to its brand, the website lists eight Nobel laureates and 19 other prominent scientists who sit on its scientific advisory board. The company also advertises research partnerships with Harvard and U.K. universities Cambridge and Oxford.

Some scientists and institutions have grown uneasy with such ties. Cambridges Milner Therapeutics Institute announced in 2017 it would receive funding from Elysium, cementing a research partnership. But after hearing complaints from faculty that the institute was associating itself with an unproven supplement, it quietly decided not to renew the funding or the companys membership to its innovation board.

The sale of nutritional supplements of unproven clinical benefit is commonplace, said Stephen ORahilly, the director of Cambridges Metabolic Research Laboratories who applauded his university for reassessing the arrangement. What is unusual in this case is the extent to which institutions and individuals from the highest levels of the academy have been co-opted to provide scientific credibility for a product whose benefits to human health are unproven.

The promise

A generation ago, scientists often ignored or debunked claims of a fountain of youth pill.

Until about the early 1990s, it was kind of laughable that you could develop a pill that would slow aging, said Richard Miller, a biogerontologist at the University of Michigan who heads one of three labs funded by the National Institutes of Health to test such promising substances on mice. It was sort of a science fiction trope. Recent research has shown that pessimism is wrong.

Mice given molecules such as rapamycin live as much as 20 percent longer. Other substances such as 17 alpha estradiol and the diabetes drug Acarbose have been shown to be just as effective in mouse studies. Not only do mice live longer, but, depending on the substance, they avoid cancers, heart ailments and cognitive problems.

(MELANIE MAXWELL FOR KHN)Until about the early 1990s, it was kind of laughable that you could develop a pill that would slow aging, says University of Michigan biogerontologist Richard Miller. It was sort of a science fiction trope. Recent research has shown that pessimism is wrong.

But human metabolism is different from that of rodents. And our existence is unlike a mouses life in a cage. What is theoretically possible in the future remains unproven in humans and not ready for sale, experts say.

History is replete with examples of cures that worked on mice but not in people. Multiple drugs, for instance, have been effective at targeting an Alzheimers-like disease in mice yet have failed in humans.

None of this is ready for prime time. The bottom line is I dont try any of these things, said Felipe Sierra, the director of the division of aging biology at the National Institute on Aging at NIH. Why dont I? Because Im not a mouse.

The hype

Concerns about whether animal research could translate into human therapy have not stopped scientists from racing into the market, launching startups or lining up investors. Some true believers, including researchers and investors, are taking the substances themselves while promoting them as the next big thing in aging.

While the buzz encourages investment in worthwhile research, scientists should avoid hyping specific [substances], said S. Jay Olshansky, a professor who specializes in aging at the School of Public Health at the University of Illinois at Chicago.

Yet some scientific findings are exaggerated to help commercialize them before clinical trials in humans demonstrate both safety and efficacy, he said.

Its a great gig if you can convince people to send money and use it to pay exorbitant salaries and do it for 20 years and make claims for 10, Olshansky said. Youve lived the high life and get investors by whipping up excitement and saying the benefits will come sooner than they really are.

Promising findings in animal studies have stirred much of this enthusiasm.

Research by Sinclair and others helped spark interest in resveratrol, an ingredient in red wine, for its potential anti-aging properties. In 2004, Sinclair co-founded a company, Sirtris, to test resveratrols potential benefits and declared in an interview with the journal Science it was as close to a miraculous molecule as you can find. GlaxoSmithKline bought the company in 2008 for $720 million. By the time Glaxo halted the research in 2010 because of underwhelming results with possible side effects, Sinclair had already received $8 million from the sale, according to Securities and Exchange Commission documents. He also had earned $297,000 a year in consulting fees from the company, according to The Wall Street Journal.

At the height of the buzz, Sinclair accepted a paid position with Shaklee, which sold a product made out of resveratrol. But he resigned after The Wall Street Journal highlighted positive comments he made about the product that the company had posted online. He said he never gave Shaklee permission to use his statements for marketing.

Sinclair practices what he preaches or promotes. On his LinkedIn bio and in media interviews, he describes how he now regularly takes resveratrol; the diabetes drug metformin, which holds promise in slowing aging; and nicotinamide mononucleotide, a substance known as NMN that his own research showed rejuvenated mice.

Of that study, he said in a video produced by Harvard that it sets the stage for new medicines that will be able to restore blood flow in organs that have lost it, either through a heart attack, a stroke or even in patients with dementia.

In an interview with KHN, Sinclair said hes not recommending that others take those substances.

Im not claiming Im actually younger. Im just giving people the facts, he said, adding that hes sharing the test results from InsideTrackers blood tests, which calculate biological age based on biomarkers in the blood. They said I was 58, and then one or two blood tests later they said I was 31.4.

InsideTracker sells an online age-tracking package to consumers for up to about $600. The companys website highlights Sinclairs support for the company as a member of its scientific advisory board. It also touts a study that describes the benefits of such tracking, which Sinclair co-authored.

Sinclair is involved either as a founder, an investor, an equity holder, a consultant or a board member with 28 companies, according to a list of his financial interests. At least 18 are involved in anti-aging in some way, including studying or commercializing NAD boosters. The interests range from longevity research startups aimed at humans and even pets to developing a product for a French skin care company to advising a longevity investment fund. Hes also an inventor named in the patent licensed by Harvard and the Mayo Clinic to Elysium, and one of his companies, MetroBiotech, has filed a patent related to nicotinamide mononucleotide, which he says he takes himself.

Sinclair and Harvard declined to release details on how much money he or the university is generating from these disclosed outside financial interests. Sinclair estimated in a 2017 interview with Australias Financial Review that he raises $3 million a year to fund his Harvard lab.

Liberty Biosecurity, a company he co-founded, estimated in Sinclairs online bio that he has been involved in ventures that have attracted more than a billion dollars in investment. When KHN asked him to detail the characterization, he said it was inaccurate, without elaborating, and the comments later disappeared from the website.

Sinclair cited confidentiality agreements for not disclosing his earnings, but he added that most of this income has been reinvested into companies developing breakthrough medicines, used to help my lab, or donated to nonprofits. He said he did not know how much he stood to make off the Elysium patent, saying Harvard negotiated the agreement.

Harvard declined to release Sinclairs conflict-of-interest statements, which university policy requires faculty at the medical school to file in order to protect against any faculty bias that could heighten the risk of harm to human research participants or recipients of products resulting from such research.

We can only be proud of our collaborations if we can represent confidently that such relationships enhance, and do not detract from, the appropriateness and reliability of our work, the policy states.

Elysium advertises both Harvards and Sinclairs ties to its company. It was co-founded by Massachusetts Institute of Technology professor Leonard Guarente, Sinclairs former research adviser and an investor in Sinclairs Sirtris.

Echoing his earlier statements on resveratrol, Sinclair is quoted on Elysiums website as describing NAD boosters as one of the most important molecules for life.

Supplement loophole?

The Food and Drug Administration doesnt categorize aging as a disease, which means potential medicines aimed at longevity generally cant undergo traditional clinical trials aimed at testing their effects on human aging. In addition, the FDA does not require supplements to undergo the same safety or efficacy testing as pharmaceuticals.

The banner headline on Elysiums website said that clinical trial results prove safety and efficacy of its supplement, Basis, which contains the molecule nicotinamide riboside and pterostilbene. But the companys research did not demonstrate the supplement was effective at anti-aging in humans, as it may be in mice. It simply showed the pill increased the levels of the substance in blood cells.

Elysium is selling pills to people online with the assertion that the pills are clinically proven said ORahilly. Thus far, however the benefits and risks of this change in chemistry in humans is unknown.

Many interventions that seem sensible on the basis of research in animals turn out to have unexpected effects in man, he added, citing a large clinical trial of beta carotene that showed it increased rather than decreased the risk of lung cancer in smokers.

Elysiums own research documented a small but significant increase in cholesterol, but added more studies were needed to determine whether the changes were real or due to chance. One independent study has suggested that a component of NAD may influence the growth of some cancers, but researchers involved in the study warned it was too early to know.

Guarente, Elysiums co-founder and chief scientist, told KHN he isnt worried about any side effects from Basis, and he emphasized that his company is dedicated to conducting solid research. He said his company monitors customers safety reports and advises customers with health issues to consult with their doctors before using it.

If a substance meets the FDAs definition of a supplement and is advertised that way, then the agency cant take action unless it proves a danger, said Alta Charo, a former bioethics policy adviser to the Obama administration. Pharmaceuticals must demonstrate safety and efficacy before being marketed.

A lot of what goes on here is really, really careful phrasing for what you say the thing is for, said Charo, a law professor at the University of Wisconsin. If theyre marketing it as a cure for a disease, then they get in trouble with the FDA. If theyre marketing it as a rejuvenator, then the FDA is hamstrung until a danger to the public is proven.

This is a recipe for some really unfortunate problems down the road, Charo added. We may be lucky and it may turn out that a lot of this stuff turns out to be benignly useless. But for all we know, itll be dangerous.

The debate about the risks and benefits of substances that have yet to be proven to work in humans has triggered a debate over whether research institutions are scrutinizing the financial interests and involvement of their faculty or the institution itself closely enough. It remains to be seen whether Cambridges decision not to renew its partnership will prompt others to rethink such ties.

Flier, the former dean of Harvard Medical School, had earlier heard complaints and looked into the relationships between scientists and Elysium after he stepped down as dean. He said he discovered that many of the board members who allowed their names and pictures to be posted on the company website knew little about the scientific basis for use of the companys supplement.

Flier recalls that one scientist had no real role in advising the company and never attended a company meeting. Even so, Elysium was paying him for his role on the board, Flier said.

Caroline Perry, director of communications for Harvards Office of Technology Development, said agreements such as Harvards acceptance of research funds from Elysium comply with university policies and protect the traditional academic independence of the researchers.

Harvard enters into research agreements with corporate partners who express a commitment to advancing science by supporting research led by Harvard faculty, Perry added.

Like Harvard, the Mayo Clinic refused to release details on how much money it would make off the Elysium licensing agreement. Mayo and Harvard engaged in substantial diligence and extended negotiations before entering into the agreement, said a Mayo spokeswoman.

The company provided convincing proof that they are committed to developing products supported by scientific evidence, said the spokeswoman, Duska Anastasijevic.

Guarente of Elysium refused to say how much he or Elysium was earning off the sale of the supplement Basis. MIT would not release his conflict-of-interest statements.

Private investment funds, meanwhile, continue to pour into longevity research despite questions about whether the substances work in people.

One key Elysium investor is the Morningside Group, a private equity firm run by Harvards top donor, Gerald Chan, who also gave $350 million to the Harvard School of Public Health.

Billionaire and WeWork co-founder Adam Neumann has invested in Sinclairs Life Biosciences.

An investment firm led by engineer and physician Peter Diamandis gave a group of Harvard researchers $5.5 million for their startup company after their research was publicly challenged by several other scientists.

In its announcement of the seed money, the company, Elevian, said its goal was to develop new medicines that increase the activity levels of the hormone GDF11 to potentially prevent and treat age-related diseases.

It described research by its founders, which include Harvards Amy Wagers and Richard Lee, as demonstrating that replenishing a single circulating factor, GDF11, in old animals mirrors the effects of young blood, repairing the heart, brain, muscle and other tissues.

Other respected labs in the field have either failed to replicate or contradict key elements of their observations.

Elevians CEO, Mark Allen, said the early scientific data on GDF11 is encouraging, but drug discovery and development is a time-intensive, risky, regulated process requiring many years of research, preclinical [animal] studies, and human clinical trials to successfully bring new drugs to market.

Flier worries research in the longevity field could be compromised, although he recognizes the importance and promise of the science. He said hes concerned that alliances between billionaires and scientists could lead to less skepticism.

A susceptible billionaire meets a very good salesman scientist who looks him deeply in the eyes and says, Theres no reason why we cant have a therapy that will let you live 400 or 600 years, Flier said. The billionaire will look back and see someone who is at MIT or Harvard and say, Show me what you can do.

Despite concerns about the hype, scientists are hopeful of finding a way forward by relying on hard evidence. The consensus: A pill is on the horizon. Its just a matter of time and solid research.

If you want to make money, hiring a sales rep to push something that hasnt been tested is a really great strategy, said Miller, who is testing substances on mice. If instead you want to find drugs that work in people, you take a very different approach. It doesnt involve sales pitches. It involves the long, laborious, slogging process of actually doing research.

KHN senior correspondent Jay Hancock contributed to this report.

Kaiser Health News (KHN) is a nonprofit news service covering health issues. It is an editorially independent program of the Kaiser Family Foundation that is not affiliated with Kaiser Permanente.

Calling all HuffPost superfans!

Sign up for membership to become a founding member and help shape HuffPost's next chapter

Continued here:
A Harvard Geneticist Wants To Sell A Magical ... - HuffPost

Jennifer Aniston: How The Morning Show felt like 20 years of therapy – The Detroit News

Los Angeles Jennifer Aniston keeps a shoe box and a pair of gloves handy because well, it just happened again. A bird has flown into one of the glass windows of her midcentury Bel-Air home, and Aniston is grabbing the makeshift rescue kit and heading outside. Oh, honey. Hi, little guy. Shes struggling and she cant get up. Theres a pause. Im so sorry. Can you hold on a moment? Aniston mutes our call, returning in five minutes. We did it, Glenn. We saved him. He might need a wing check, but I think hes going to be OK.

Jennifer Aniston in "The Morning Show."(Photo: Apple TV)

That Aniston has what she calls a Dr. Dolittle plan for the wayward birds in her life surprises exactly no one who knows her. Just before the moment of bird distress, Aniston was peppering me with questions about exercise, hydration and mental and physical well-being. I love that shes interviewing you about your health regime, Kristin Hahn, Anistons longtime friend and producing partner, says a couple of days later. That sounds about right. If you give this woman a problem to solve, she will spend whatever time it takes to come up with a plan and tell you how to deal with it. And I mean, any kind of problem. We call her Dr. Aniston.

Aniston solved the primary problem of her own career how to find a role that would challenge her in ways she could never expect and make the public not exactly forget that she played Rachel on Friends, because that beloved sitcom isnt going anywhere in our lifetime, but at least showcase her talent in a way that might surprise people. Anistons turn as network morning anchor Alex Levy on The Morning Show, the flagship series in the Apple TV+ streaming lineup, did just that, earning Aniston the best reviews of her career, an Emmy nomination and a SAG Award in January.

That show was 20 years of therapy wrapped into 10 episodes, says Aniston, 51. There were times when I would read a scene and feel like a whole manhole cover was taken off my back.

Steve Carell and Jennifer Aniston in "The Morning Show."(Photo: Apple TV)

You might guess that Aniston could relate to playing a famous woman whose every move is scrutinized and judged, who grapples daily with people projecting their ideas of what her life should be (Brad & Jen-aissance) versus the authentic journey shes trying to forge, whose sell-by date expired years ago (at least, according to Billy Crudups dismissive network exec) and who, in one of The Morning Shows most memorable scenes, tells her bosses that shes really, really tired of being underestimated.

Uh-huh, she says, employing the comic timing she honed during a decade on Friends and innumerable movie rom-coms. I see where youre going.

And she gladly goes there with me. The Morning Show, which she helped build from the ground up as a producer, felt like a two-year cleanse that forced Aniston to examine how shes handled fame over the last three decades and decide that she could improve it.

Cathartic, yes, and also interesting for me to look at how I always have tried to normalize being fine and everythings great, you know, this is all normal, and then there are moments when you have your private breakdown or your Calgon, take me away moments, Aniston says. To actually look at it from an actor brain observing it and acknowledging it, I had to look at it as opposed to pretending it doesnt exist.

Aniston then dives into the scene in The Morning Shows second episode where Alex melts down in a limo on the way to an industry awards event being held in her honor. Ostensibly, the anger stems from the impracticality of the tiny purses women carry down the red carpet. But its really about her anxiety over having to put on a happy face during a time when shed rather be hiding under the covers. Aniston is utterly convincing in the moment, raw, empathetic and, of course, funny, when she turns on a dime at the onset of tears and sobs, Oh, Jesus, I cant cry! because it would ruin the makeup her stylist had spent hours applying.

There have been moments not to that level of hysteria but moments of I dont want to f ing go here, I dont want to walk out onto the carpet, I dont want to be seen, I dont want to be looked at and everyones going to be talking about me and judging me thats real, Aniston says. I just loved being able to walk into it and lean into it and not be ashamed of it, but actually just it was like she lets out a sound of sublime satisfaction. Ooooooooooh.

There were times during the series first season when Morning Show showrunner Kerry Ehrin would check in and ask Aniston: Are we pushing it? Are we taking it too far? And Aniston would answer that it was never too far. Keep it coming.

I do think I glean emotional structure from people, Ehrin says, and after spending time with her, I felt certain instincts about writing the character. And its hard to say whether that comes from a conversation or something I saw 20 years ago that she did.

Says Hahn: I was so moved to tears so many times, just watching behind the monitor and brought to tears at the level of bravery of being that truthful. I know her well enough to know when shes being concerned about what other people think, and she just let everything go. She exorcised a lot of conflict through this character.

The Morning Show had begun filming its second season earlier this year before COVID-19 shut down production in March. Aniston says the break proved fortuitous, because it allowed them to incorporate the pandemic into the story and reflect the unease everyone felt when they were shooting the seasons first two episodes. Pre-COVID and post-COVID are different universes, Ehrin says, and theres no way a topical program like The Morning Show could ignore that. What will that look like? Youre just taking the best guess of what you think will be an effective place to go with the storytelling and let the characters guide you, Ehrin says.

Anistons post-COVID-19 life looks like this right now: She has a bubble of four families that rotate among their homes and never go outside the pod. The kids have grown up together and know one another, so they have a good time, and its all lovely, Aniston says. Shes reading, watching a ton of TV, veering between things like Queer Eye for the Straight Guy and the James Baldwin-centered examination of American racism, I Am Not Your Negro. And Lenox Hill, the Netflix medical docuseries, because Aniston was addicted to Trauma: Life in the E.R. back in the day and loves watching the stories of doctors and health care workers, particularly at this moment in time.

Jennifer Aniston and Steve Carell in "The Morning Show," streaming on Apple TV+.(Photo: Apple TV+, TNS)

Last summer and into the early fall, Aniston hosted a series of salons, Jen Talks, she calls them, inviting a few dozen friends to her home to listen to people like Jessica Yellin discuss politics or Jay Shetty distill what he learned as a monk or David Sinclair offer advice on longevity. Because Aniston has her eye on the long game. And she plans on winning.

I look at my dad, who just turned 87, and he is Greek stubborn, fabulous, all those things from that generation but, you know, I think they could be a little healthier. Hes going to be so mad at me. Aniston pauses, laughing. But shes not stopping. You know, my mom, cmon, none of you guys took care of yourselves. But they didnt know any better. And now we know. So whats our excuse? Its about just knowing what you put inside your body, exercising my father, never, ever they didnt know you could keep your bones strong, never mind being fit and fitting into a size-whatever.

Im going to be in my 80s or 90s or maybe now even my 100s at this rate, Aniston continues, and I dont want to be wheeling around. I would like to be vibrant and thriving.

And we talk more about bone density and cellular regeneration and how 90 might soon be the new 70 and about a new level of consciousness thats getting birthed right now and planetary alignment and how these troubling times are temporary and this too shall pass and then our time together is done. But not before Dr. Aniston leaves me with one last prescription: Rich Roll podcast. David Sinclair. Longevity. Its 21/2 hours long. And I have a bad feeling Im going to be giving up pasta after I finish listening to it.

Read or Share this story: https://www.detroitnews.com/story/entertainment/television/2020/08/20/jennifer-aniston-morning-show-felt-like-therapy/113397792/

Visit link:
Jennifer Aniston: How The Morning Show felt like 20 years of therapy - The Detroit News

Fife woman breached Asbo by having illicit party at home during lockdown – The Courier

A selfish neighbour breached her Asbo by inviting friends round for an illicit party during the coronavirus lockdown.

Shannon Mullen, 25, was caught with more people in her home than she was allowed under the strict terms of her anti-social behaviour order.

Mullen who had made her neighbours lives a misery broke the Asbo by having more than two people in her home on May 10.

Dundee Sheriff Court was told that Mullen had the Asbo imposed on March 25 after a series of incidents at the property in Burns Begg Street, Kinross.

Depute fiscal Lisa Marshall told the court: She has previous convictions. She has been making her neighbours lives a misery.

Mullen was banned from shouting, swearing, screaming, slamming doors, arguing, fighting, banging walls and playing loud music under the terms of the interim order.

It also prevented her from having others banging the external door and shouting and swearing at the property.

But it was the condition limiting her visitor numbers which she admitted breaking by having three people in the house during the pandemic lockdown.

Solicitor David Sinclair, defending, said: Things have been difficult with her neighbour. I am not sufficiently familiar with the case to know whats caused that.

She accepts there were three persons in her house. Her intention is to go to Kelty and live with her mother, which may give her neighbours some respite.

Mullen, now of Croftangry Road, Kelty, had sentence deferred and was ordered to be of good behaviour for six months.

Follow this link:
Fife woman breached Asbo by having illicit party at home during lockdown - The Courier

Drug Use is Transmitted from Old to Young – UPJ Athletics

Up until now, research into the demographics of drug use has focused more on age, finding that midlife is the riskiest time for drug-related death, but Burke and colleagues saw that the year a person was born also has a large effect.

These phases map onto the previously identified drug waves that came with the waxing and waning popularity of prescription opioids, heroin and fentanyl, each in turn.

Peering within each generation, Jalal and colleagues saw a steady march toward greater overdose risk at younger ages for each successive birth year, which they found quite surprising.

Theres no reason why the lines should be fanning like this, Jalal said. If you look at breast cancer, for example, or any other mortality curves, they dont look like that.

Its not clear why this is happening, Jalal said, but the pattern is too clean to chalk up to chance. And an overall rise in drug overdose deathsalthough that is happening in the background of these datadoes not explain away the results presented in this study.

Burke uses an analogy borrowed from infectious diseases to explain the progressive shift of drug overdose deaths to younger ages.

Burke hopes that the highly regular patterns uncovered in this analysis will give policy makers a tool for testing whether their measures to curb drug overdose deaths are working over the long termany effective intervention should disrupt the pattern.

Additional authors on the study are Jeanine Buchanich, David Sinclair and Mark Roberts, all of Pitt Public Health. Funding was provided by theNational Center for Advancing Translational Sciencesand theRobert Wood Johnson Foundation.

See the original post:
Drug Use is Transmitted from Old to Young - UPJ Athletics

Carole Carson: Adventures in Aging Seven myths about getting older – The Union of Grass Valley

How many of these myths do you accept as reality?

Myth 1: When it comes down to it, aging is just another disease, asserts professor David Sinclair, PhD, a Harvard professor.

He is convinced that aging, like obesity, is a pathological condition that scientists will eradicate.

Reality: If aging is a disease, it must be highly contagious because all my patients get it, says Dr. Todd Bouchier, a Grass Valley physician. And everyone over the age of 65 has an advanced case.

Support Local JournalismDonate

Humor aside, Dr. Bouchier continues, aging is not a disease. Over time, mountains crumble, barns collapse, and cells degenerate. Aging is a fact of nature. Scientists get excited about the possibility of escaping the preprogrammed aspects of cellular aging. No doubt, well make gains and eventually live longer but wont eliminate aging. Making the final years as meaningful as possible is the goal.

Myth 2: All seniors are alike and are best described as sexless, toothless, prune juice-drinking dribblers who watch daytime television and shuffle like Tim Conway.

Reality: People live more diverse lives over time. People in their 20s are more alike than folks in their 80s. We even age differently. Four distinct ageotypes metabolic, immune, hepatic (liver), and nephrotic (kidney) determine how and where in the body biologic aging occurs.

As for sex, studies show that seniors enjoy sex and variations of sexual activity beyond middle age. Moreover, the need for intimacy touching, hugging, or holding hands is timeless.

Myth 3: Old timers are a drain on society, sucking up resources the younger folks need. The fewer seniors in a community, the healthier it is. The coronavirus can thin the herd.

Reality: Over 1,200 nonprofit and 501(c) organizations operate in Nevada County, enriching our community in immeasurable ways. Funding and volunteer support (estimated at 10,000 hours annually) rely heavily on seniors for these civic and social activities.

Plus, increasing numbers of seniors work. And even those who arent on a payroll still work as grandparents and caregivers.

As for welfare, older people have emerged as the wealthiest segment of our population.

Myth 4: Seniors dont need or buy much, hence, commercials focus on young people, except for depressing pharmaceutical ads.

Reality: The 65-and-older population is the mother of all untapped markets, according to Barrons. In 2015, the spending of Americans ages 50 and up accounted for nearly $8 trillion worth of dollars spent. By 2030, the 55-and-older population will have accounted for half of all domestic consumer spending growth.

And even when household income for older people is at or below the median, they have as much or more disposable income as young people with the same income.

Myth 5: You cant teach an old dog new tricks. Technology is wasted on seniors. Humans are born with a finite number of brain cells that die off with aging.

Reality: Learning patterns may change and the speed of learning may diminish, but the basic capacity to learn is retained. As for technology, in 2000, 14% of those aged 65 and older were internet users; now 73% are.

Moreover, through the process of neurogenesis, brain cells adapt and reconnect even regrow and replenish. Thanks to brain plasticity, we old dogs can teach young dogs some new tricks!

Myth 6: To be old is to be irritable and grumpy. Depression is inevitable given the declining trajectory of deteriorating mental and physical health.

Reality: Depression is not a normal part of aging but rather an illness requiring treatment. The course of depression in the elderly is identical to that of younger persons, and the response to treatment appears as positive as that of people in other life stages.

Myth 7: Senior moments signal the onset of dementia, a disease no one escapes if they live long enough. The lights are still on, but the voltage is low.

Reality: Forgetfulness occurs at all ages, but were more inclined to notice as we age. The good news is that the rate of dementia is declining and occurring at older and older ages. Only 5% of people over age 65 have dementia. In addition, some memory loss is caused by medications and medical conditions unrelated to aging.

The best news is that aging and dementia are not inextricably linked. Evidence is growing that regular exercise, healthful eating, and mentally challenging activities can preserve cognitive functions independent of age.

Accepting these myths holds us back. It cuts us off from opportunities that are jumping up and down in front of us seeking to get our attention. Knowing the truth, on the other hand, sets us free to explore our options while we celebrate the simple joy of being alive.

Next Month: Your body over time

Carole Carson, Nevada City, is an author, former AARP website contributor, and leader of the 1994 Nevada County Meltdown. Contact: carolecarson41@gmail.com.

Read more from the original source:
Carole Carson: Adventures in Aging Seven myths about getting older - The Union of Grass Valley

Hide and Hedonism invite guests to a virtual wine dinner – Spear’s WMS

The Mayfair restaurant and wine boutique invite diners to a virtual four-course dinner with head sommelier Julien Sarrasin

Guests of Mayfair restaurant Hide can now enjoy a four-course menu prepared by Ollie Dabbous and paired with fine wines from Hedonism all in the comfort of their own home.

The Michelin-starred restaurant and its sister wine merchant Hedonism have upped the ante in the high-end food delivery stakes by offering diners the chance to join HIDE at HOMEs head sommelier Julien Sarrasin by live video feed on Wednesday 13th May.

Sarrasin will introduce each dish and discuss each of the wines in turn. Diners will learn about the winemaker, the grape varieties and why each fine wine was selected to pair with a particular course.

The menu starts with a chilled pine broth amuse bouche with strawberries, avocado, basil and pistachio. The starter is scallop tartare with Exmoor caviar, followed by Champagne-poached cornfed chicken, sptzle and black truffle. Dessert is a baked Alaska made with cascara, coffee and pecan.

Wines will be delivered one or two days before the date of the event. The meal will be delivered on the evening of Wednesday 13th May. The offer is limited to a list of London postcodes which is available on the HIDE at HOME site.

The menu will be prepared by Ollie Dabbous and his team at Hide. The chef opened his first restaurant, Dabbous, in 2012 and earned his first Michelin star. After closing Dabbous in 2017, the chef joined forces with Hedonism Wines to launch Hide, which earned a Michelin star within six months of opening in 2018.

The virtual wine dinner from HIDE at HOME is just one in a series of virtual events being run by the restaurant. Others include a spirit tasting to discover the smoky drams of Scotland with specialist Tom Olive, a winemaker tasting with the Chef de Cave at Charles Heidsieck, Cyril Brun, and a whisky tasting with The Macallans owner David Sinclair.

Web: hide.co.uk/home

Original post:
Hide and Hedonism invite guests to a virtual wine dinner - Spear's WMS

Budget realities from COVID-19 cut $40.6 million from Prince William budgets – Inside NoVA

Prince William County will leave the rate on real estate taxes unchanged for the next fiscal year, as the budget reality of the COVID-19 pandemic forced supervisors to ditch new spending and a proposed tax rate increase.

More than 25 Prince William County residents who talked remotely to the board of county supervisors Tuesday were divided with many supporting a proposal to keep the real estate tax rate steady in an effort to fund schools and social services, while others said the county should decrease the tax rate as thousands in the county have lost jobs and others face furloughs and an uncertain future amid the COVID-19 pandemic.

The board adopted its $1.09 billion budget for fiscal year 2021 that starts July 1.

The board adopted the same real estate tax rate as this fiscal year: $1.125 for every $100 of assessed value. That doesnt mean that taxes wont go up. Residents who have seen property values climb will see an increase in their tax bill, about a $177 increase on the average residential tax bill.

The vote was 5-3. Supervisors Jeanine Lawson, R-Brentsville, Pete Candland, R-Gainesville, and Yesli Vega, R-Coles, argued for a tax rate of $1.085 per every $100 of value. Democratic supervisors argued the cuts would limit county services.

Supervisors also voted to increase the tax rate on computer equipment by 10 cents to $1.35 per every $100 of assessed value a charge that primarily affects data centers.

The adopted budget has $40.6 million less than staff had proposed on Feb. 18. Of that money, $22.7 million was expected to be added to school division revenue.

The board ended up allocating $629.6 million to the division, including $625.3 million that is part of the countys revenue sharing agreement, along with additional funding for class size reduction, costs related to the 13th high school and more.

Chair Ann Wheeler said she expects the board will have to revisit its budget every quarter due to the uncertainty of the pandemic.

When the board adopted its current budget last year, Republicans held a 6-2 majority. Now, Democrats hold a 5-3 majority.

The budget included $7 million for pay increases for about 1,500 employees, raises that were recommended to the board to ensure employees are being paid equally for similar work and to make sure pay is competitive with other governments in the region.

Supervisor Andrea Baileys proposal to add an additional $150,000 for community partners nonprofits such as ACTS in Dumfries to the existing proposal of $92,904 for fiscal year 2021 was also approved.

David Sinclair, the countys director of the office of management and budget, told the board the fiscal 2021 budget means about $36 million less than the school board adopted as part of its recommended budget. The school board is waiting to adjust its spending plan until after the county and the state determine how deep cuts will go.

On Feb. 18, County Executive Christopher Martino proposed a budget based on a 2-cent increase to the real estate tax rate. After the coronavirus, Wheeler sought a budget that kept the tax rate unchanged.

Among items cut was a 3% merit raise for county staff. Martino also has implemented a hiring freeze unless the position is required for public safety related to the pandemic, focused spending on core services, and postponed large construction projects that are not under contract, among other measures.

Staff project the county will see $14.2 million less in revenue in fiscal year 2021. The county also expects to receive $2.4 million less in revenue prior to June 30, when fiscal 2020 ends.

In Prince William Health District, which includes the county, Manassas and Manassas Park, reported 1,677 people who tested positive for COVID-19, 183 people were hospitalized and 23 people have died due to the virus, according to the Virginia Department of Health.

According to the Virginia Employment Commission, over 28,600 Prince William residents filed for unemployment benefits between March 15 and April 18.

The board also approved the request from Supervisor Andrea Bailey, D-Potomac, for $2 million for the environmental and preliminary design for the Van Buren Road extension project. That funding is coming from the Northern Virginia Transportation Authority.

Supervisor Margaret Franklin, D-Woodbridge, proposed on April 21 to starta small business program so the county can offer $10,000 loans and grants through its Industrial Development Authority. This week,theboard approved $1 million for that program starting this fiscal year 2020 and carrying over any funds to fiscalyear 2021. Also starting this fiscal year, is a program pitched by Franklin to dedicate $500,000 to offer rental or utility assistance for people who are low income or elderly or disabled.

See the rest here:
Budget realities from COVID-19 cut $40.6 million from Prince William budgets - Inside NoVA

‘Refreshingly honest’ dealer who ran Perth drug den will be sent home to Poland – The Courier

A dealer who moved from Poland to set up a drug den in a housing association flat has been ordered to hand over more than 5,000 before he is booted out of Scotland.

Kamil Morawski has been told to pay back 5,460 he made dealing drugs from the flat in Perth.

Morawski, who was described as refreshingly honest when a sheriff jailed him for four and a half years, will also be extradited back to Poland

Morawski bluntly told police who raided his Perth home that he was a drug dealer and had been in business for months.

Perth Sheriff Court was told Morawski was given a housing association flat when he moved to Scotland and used it to set up a large-scale drug den peddling ecstasy, speed and cannabis.

Morawski, 31, was found with 40,000 worth of drugs after converting the flat into the centre of his drug dealing operation.

The father of one who had served prison terms in his homeland for drug-related crimes was caught with nearly two kilos of speed, worth nearly 20,000.

He had more than 1,000 ecstasy tablets and more than a kilo of cannabis in the McCallum Court flat.

Depute fiscal Charmaine Gilmartin told Perth Sheriff Court 1,120 ecstasy tablets were recovered with a potential value of 11,200, along with 1,945 grammes of amphetamine worth 19,450.

The total cannabis recovered weighed 1,309 grammes and had a maximum value of 13,090. Morawski had also stuffed more than 5,000 cash under his mattress.

She said: The accused gave full answers, stating that he was a drug dealer and sold cannabis, amphetamine and E.

He stated he had been dealing for around six months for financial gain.

Morawski, a prisoner at Perth, admitted three charges of being concerned in the supply of cannabis, amphetamine and ecstasy between January 31 and July 31 last year.

Solicitor David Sinclair, defending, said: He was seeking to improve his familys life and took a short way of doing so.

Sheriff Lindsay Foulis said: You have held your hands up and accepted responsibility at the earliest stage.

You do not shy away from taking responsibility.

Nor do you try and mask your reasons for your actions in any way and such honesty, to put it bluntly, is refreshing.

Read more:
'Refreshingly honest' dealer who ran Perth drug den will be sent home to Poland - The Courier

Has Harvard’s David Sinclair Found the Fountain of Youth?

Health

Not yetbut he sure is getting rich, famous, and having a blast while trying.

Portrait by Ken Richardson

Like any dreamer, David Sinclair has a tendency to live in the future. The first time that thought crossed my mind, we were hurtling toward Worcester in his Tesla, on our way to visit one of his many companies working on an antidote to aging. Sinclair told me hed recently discovered, using a health-tracking device, that hes shaved a decade off his life: Biologically speaking, he is now 40, not 50. I took a good look at him. Except for the pillow he sat on while he drove, the wrinkles that formed around his eyes when he flashed his mischievous grin, and the note scrawled on the back of his hand (lest he forget something he has to do), there was no way in hell he looked anywhere near 50. He is slight of build, with nary a gray hair, and bears a passing resemblance to that forever child Alfred E. Neuman. He even says he feels like a kid, too.

I had skipped breakfast that morning to get a feel for what its like to be Sinclair, whose habit of not eating anything until the afternoonalong with ingesting a mysterious medley of pillsis one of his many life-extending practices. When I asked about one of the drugs he takes, he reached into his pocket and pulled out a capsule filled with a white powder that he packages himself in his lab. He has told reporters that the substance inside is a miracle molecule. I plucked it from his hand and put it in my own. It felt so light in my palm. So easy to believe. And that is precisely the problem.

From time immemorial, people have been on a fantastical quest for a substance that would extend life, or even grant immortality. The medieval alchemists sought the elixir of life. Explorer Ponce de Leon looked for the fountain of youth in what is now the southern United States but, in an ironic twist of fate, found Florida, a place where people go to grow old and die. As the centuries wore on, traffic in life-extending substances and practices became the clear bailiwick of snake-oil salesmen, charlatans, and quacks.

More recently, though, longevity has become the stuff of legitimate science. Sinclair is a superstar among a group of researchers who have harnessed science and technologys latest advances in an effort to parse out, for the very first time, the biological mechanisms of aging in hopes of slowing or even reversing the process. The goal of this field is not to make us young for youths sake, but to address the single greatest risk factor for heart disease, cancer, diabetes, dementia, and many other forms of modern-day suffering: aging. This radical new thinking about medicine maintains that if we can address the upstream cause of these diseases, we can cure them all at once (instead of relying on the current Whack-a-Mole approach) and increase the number of years people live with good health. But it is also true, experts say, that eliminating all of these diseases of aging will make people live longer. We are on the verge of a public health breakthrough of the kind we have never seen before, says S. Jay Olshansky, a professor of public health who studies demographics and aging at the University of Illinois at Chicago. It is not trivial. This is bigtime.

Sinclair deserves much of the credit for getting the field to where it is today. The Australian-born Harvard Medical School professor of genetics has had countless discoveries published in the most respected scientific journals in the world and has received dozens of scientific prizes and honors. Last year he was appointed an Officer of the Order of Australia for his contributions to humanity. Wealthy investors, including WeWork cofounder Adam Neumann, have bet hundreds of millions of dollars on his science and invested in the 17 companies hes founded. When Sinclairs book, Lifespan: Why We Ageand Why We Dont Have To, was released in September, it reached number 11 on the New York Times bestseller list in just over a week.

At the same time, Sinclair is one of sciences most controversial figures, regarded by many as a slick salesman who overhypes his work and its potential. Some critics cringe when he speaks of miracle molecules and everlasting life. Others whisper that his science may not be completely sound. Still others roll their eyes over his habit of taking drugs that havent been proven to delay aging in anyone who isnt a mouse. The prevailing wish among his doubters is for him to simply keep his mouth shut. He is a complicated guy, says Steven Austad, a professor of biology who studies aging at the University of Alabama at Birmingham and is a friend of Sinclairs. Hes a superb scientist, as well as a superb salesman. You talk to him about science and you wont find many more knowledgeable, incisive experimentalists as David. And then you can listen to the stuff he says on TV and be like, What the hell is he talking about?

Sinclairs bold statements and pill-popping habits have ruffled feathers closer to home, tooat the very institution that employs him. He does do research and he gets it published in peer-reviewed journals, and if he just did that, itd be fine, says a Harvard Medical School professor who asked to remain anonymous. But then he speaks out about how he makes himself young and says stuff that would be embarrassing for any normal scientist to say.

In other words, in an increasingly legitimate field of science desperate to distance itself from the alchemists and quacks of yore, Sinclair presents somewhat of a problem. As a brilliant scientist in the lab, he is a major asset to his fields eternal quest for legitimacy. Let loose in the world, though, the self-described Star Trek wannabe, whos eager for the future to arrive as fast as possible, is somewhat of a liability. He may very well be the man who will unlock the secret to extending life some 10, 20, or even 30 yearsso long as he doesnt get lost searching for the fountain of youth along the way.

David Sinclair hanging out with Joe Rogan after appearing on his podcast. / Photo from Instagram

Sinclair can remember with startling clarity the day he first learned about death. He was with his beloved grandmother at her home in Turramurra, a leafy suburb of Sydney on the edge of the bush. They were seated on the floor playing when she told him his cat would only live to about 15. He was shocked. And the news only got worse. Everybody dies, she told him.

It is not surprising for children to be disturbed when they learn about mortality, but most of them move on, squirreling away the fear and dread until it comes bubbling back to the surface with the appearance of gray hairs, knee pain, and mental lacunas. Sinclairs trajectory was slightly different. In a sense, he never got over it.

While his biochemist parents worked, Sinclair spent most of his childhood with his fun-loving, free-spirited grandmother, who admonished him to never grow up. By the time he enrolled at the University of New South Wales to study biochemistry, he was convinced that science would one day catch up with his grandmothers ideas and people would be able to stay young forever. He believed, however, that he had been born too early to see it. He told his friends at school over coffee that they were likely to be the last of thousands of generations to live the sad existence of such a short life. But no sooner had he thought it, he says, than he considered the fact that maybe he was wrong. Maybe it could happen in his lifetime, and maybe he could be a part of it. Sinclair had found his lifes purpose.

His next stop was 10,000 miles away at MIT, where at the tender age of 24 he became a postdoc in the lab of Leonard Guarente, who had just started studying aging in yeast. Sinclairs colleagues remember him as someone who was aggressive, ambitious, and tireless: He was often the first to come into the lab and stayed as long as he could before dashing to catch the last train of the night. His colleague Shin-ichiro Imai, a professor of developmental biology at the Washington University School of Medicine who first met Sinclair in Guarentes lab, says Sinclair had a keen eye for capturing novel concepts and, based on that foundation, building new lines of research faster than anyone else.

At the time, aging research, once considered a fringe science, was still in its infancy, but Sinclair was determined to propel it to legitimacy. Three years into his time at MIT, he made a groundbreaking discovery that explained, for the first time, a mechanism of aging in yeast and opened up the possibility of one day manipulating the process in humans.

From there, Sinclairs career took off like a rocket. He soon left MIT to run his own lab at Harvard Medical School and became an assistant professor of genetics, continuing to build on discoveries made at Guarentes lab about sirtuins, a family of proteins that exists in all living beings. These proteins are usually dormant, but when activated through stressors (such as restricting calories), they can enhance health and extend life in yeast. Sinclair was determined to find a substance that could mimic the effects of restricting calories in yeast, something that could one day be turned into a medicine that cures aging.

True to form, he got to work, harder and faster than anyone else, Imai says. He screened some 20,000 substances until, one day, his collaborator called to say that hed gotten a hit: resveratrol, a molecule found in red wine that has long been suspected to play a role in human health. Sinclair couldnt believe what he was hearing and knew others wouldnt, either. So he set out to disprove the finding right on his dining room table, where he lined up a series of petri dishes filled with yeast that had been fed different substances. When he discovered that the dish with yeast that lived 50 percent longer had been fed resveratrol, he cried out to his wife, I think we have found something important here.

The discovery was the start of another phase in Sinclairs career, one in which wealthy investors played as much of a role as the scientific community. In 2004, with the help of serial biotech entrepreneur Christoph Westphal, he founded a company called Sirtris Pharmaceuticals to pursue clinical-stage drugs inspired by the resveratrol molecule. At the time, it was almost unheard of for a scientist in the aging field to start a company. David was a pioneer in merging academic and commercial research, Austad says. A lot of scientists would have liked to do what David did, but they didnt know how, or have the appropriate skills to raise the money and convince the investors that this science was promising a revolution in health. David did.

Meanwhile, in his lab, Sinclair pushed his studies up the evolutionary chain into mice, and in 2006 published the paper that would change his life: a study showing that overweight rodents fed resveratrol aged slower and stayed healthier than ones that did not consume the substance. It was an instant sensation, landing on the front page of the New York Times. Sinclair gave a few dozen interviews before sitting down, relaxed and charming, for the Charlie Rose show. A 60 Minutes special on resveratrol wasnt far behind, and soon he was telling Morley Safer we could expect an FDA-approved pill in five years time. Resveratrol, he once boasted to a reporter from the magazine Science, was as close to a miraculous molecule as you can find.

In no time, Sinclair went from being a scientist toiling away in a lab to someone whom strangers recognized on the street. He became a longevity guru to legions of people hoping to glean insight about how to forestall their own mortality. And, he became rich. Sirtris went public in 2007, and one year later, pharma giant GlaxoSmithKline snatched it up for an astounding $720 million. Resveratrol had made Sinclair famous and wealthy beyond what he had ever imagined, but it was also about to turn him into one of modern sciences most polarizing figures.

David Sinclair in his lab at Harvard Medical School. / Portrait by Ken Richardson

Sinclair was sitting at his desk at Harvard one day in 2010 when a colleague called to offer his heartfelt sympathies: Pfizer scientists had just released a paper essentially saying that Sinclairs work on sirtuins was bunk. When he finally got hold of the document himself, Sinclair couldnt believe his eyes. It wasnt clear to me at all that we were wrong, he told me. We had data that showed we were right.

And yet, it wasnt the first time Sinclairs science had been challenged. A couple of years after his initial groundbreaking yeast study on resveratrol, two of his former colleagues from Guarentes lab published a paper reporting on their inability to replicate it, suggesting his conclusions were wrong. A few years later, scientists from the pharma company Amgen also raised doubts, claiming Sinclairs findings were erroneous. The Pfizer paper, though, was different. Not only did one of the biggest pharma companies in the world claim he was wrong on resveratrol, it also stated his entire theory on sirtuins was completely off. In response, Sinclair publicly questioned whether the Pfizer scientists had made mistakes running their experimentwhich didnt exactly go over well. I was criticized for saying that Pfizer doesnt know how to make a molecule right, he explained.

As the scientific community continued to raise doubts and gossip behind his back, Sinclair sank to a dark place. I spent a week in bed, he told me. I couldnt get out. My lab shrunk to, like, four people. When I asked his assistant if she remembers what it was like when the Pfizer paper came out, she sighed, looked down, and shook her head from side to side: That was devastating.

Still, its hard to keep Sinclair down for long; after all, he lives by the very idea of never say die. When he finally got out of bed, he went back into the lab to prove his naysayers wrong. The day I visited his lab, he stood with his arms crossed and a look of satisfaction on his face as he showed me a framed copy of a 2013 scientific paper that he says settled the debate and proved he was right about resveratrol activating sirtuins. In it, he showed that when scientists genetically engineered cells to change a single amino acid on a sirtuin, resveratrol had no effect on the cells. In the control cells with intact sirtuins, however, resveratrol did have an effect.

Not everyone, though, was convinced. There are lots of people in the field who harbor suspicions [about Sinclairs science], one researcher told me. It is hard to explain how the same lab on multiple occasions over a decade or so can publish multiple pieces of data that other labs cant reproduce. Whats more, GlaxoSmithKline halted a Sirtris trial in humans because of potential negative side effects and then shut the company down altogether just five years after buying it. Today, resveratrol is known as the miracle drug that wasnt.

To Sinclairs credit, none of his scientific papers have ever been retractedand none of the people who spoke to me about their suspicions of Sinclair wanted their names used. One of them admitted that it might not be his data that critics object to, but rather the way Sinclair talks about his findings. While his colleagues in the aging field overwhelmingly stick to a safe script, describing their research as a quest to extend years of health, Sinclair talks freely and excitedly about extending mortality to 150 years by the end of the centuryto say nothing of death eventually becoming a rarityboth of which critics say there is zero science to support. From his exalted platform as a scientist featured on TV and in the New York Times, Sinclair is promising the world that one day soon well be able to get a shot that reverses aging, and when it wears off and the gray hairs sprout again, well simply get a booster. Does that sound like science fiction? Something that is very far out in the future? Sinclair asks readers in his book. Let me be clear: its not.

Even the title of his bookthe part that says we dont have to ageelicited an exasperated groan from the Harvard Medical School professor. What is wrong with the guy that he is compelled to do this? he asks. Seen in the best possible way, he is totally convinced that he is the savior of mankind developing the fountain of youth. But you dont have to hype to do that. Just let the facts play out. Even his friends call him out for how he talks about his science. David is a good friend, Austad says, but I do think hes been guilty of making excessive claims.

Despite the resveratrol fiasco, Sinclair hasnt shied away from making other grandiose promises. One of his more recent molecules of interest is called NMN. It is found in every living cell and boosts levels of something called NAD+, which regulates the mitochondria, or powerhouses, in all of our cells. NAD+ declines with ageunless, that is, scientists like Sinclair can find a way to increase it. Last year, he told Time magazine that NAD+ is the closest weve gotten to a fountain of youth.

If Sinclairs public comments push past the limits of what most scientists would say, it is also true that his accomplishments in the lab continue to push the limits of science itself. When I met with Sinclair, he told me he is gearing up to publish a paper about how his lab reversed aging in rodents. He described a series of experiments using gene therapy in which he and a group of scientists were able to restore vision in mice with glaucoma as well as in other mice who had their optic nerves (which cannot grow back after the newborn period) crushed. Sinclairs team had made a handful of old mice young again.

In light of the cutting-edge experiments and advances he is making in his lab, I was surprised that Sinclair also continues to study resveratrol. It seems so yesterday. When I asked about it, he assured me with a self-confident nod that he is still bullish on resveratrol. The 2013 paper, the one on his wall he believes vindicated him, didnt get the word out far and wide enough, he says. Thats why his lab did another experimentthis time deactivating a spot on the sirtuin protein in miceto show that resveratrol does, in fact, work. He tells me hes really looking forward to that study coming out to restore faith in resveratrol. And, it seems, perhaps to restore faith in Sinclair, too. When that one comes in, he says of the forthcoming paper, Im going to dropthe mike.

If Sinclairs public comments push past the limits of what most scientists would say, it is also true that his accomplishments in the lab continue to push the limits of science itself.

As Sinclair and I neared our destination in Worcester, I had my head down, furiously scribbling in my notebook, when I felt the car swerve abruptly to the right. I looked up to see Sinclair, visibly frustrated, struggling with the Teslas steering wheel. My car appears to have been set to Mad Max mode, he said in his pitch-perfect Australian accent. I promise not to get us killed. Then he added wryly, That would be ironic.

It would, indeed. After all, Sinclair is planning on being around for a lot longer than most people think they will. He convinced his dentist to fix some wear on his teeth, a procedure that she told him shed normally reserve only for teenagers. He dedicated his book to his great-great-grandchildren, whom he is very much looking forward to meeting.

To make it until then, he practices calorie restriction, eats a mostly vegetarian diet, and tries to avoid sugar and carbs. On weekends, he exercises at the gym and then sits in a hot sauna before plunging himself into an ice-cold pool, because temperature extremes also kick our cells survival instincts into action, he says. Sinclair tracks his biomarkers regularly and takes vitamin D, vitamin K2, and aspirin. And he takes three other substances each morning: resveratrol, NMN, and metformin, a diabetes drug currently being studied for its potential anti-aging effects. The problem, critics say, is that unlike cancer drugs, for instance, nearly anyone can buy something close to the NMN and resveratrol capsules Sinclair is downing at places like the local GNC, where theyre sold as supplements alongside multivitamins and protein powder.

Sinclair diligently points out that he is not a medical doctor; that he is not recommending anyone do what he does; and that there is no definitive evidence that any of it helps humans. Still, critics say that when a scientist such as Sinclair tells people what he is taking, it is nothing short of a celebrity endorsement, those caveats notwithstanding. In his defense, he told me he gets dozens of emails and messages every day from people asking him what theyor their petsshould be taking, and that he never makes recommendations. But its also hard to imagine people would write to ask him at all if he werent talking so publiclyand so oftenabout his daily regimen. I like David a lot. Were very good friends. However, I dont think that what hes doing is right, says Felipe Sierra, the director of the aging biology division at the National Institute of Aging. I dont think that people should try it on themselves. And if they do, they shouldnt publicize it. Researchers do have a responsibility toward the public, and we should be careful about what we tell the public.

Sinclair knows he ruffles feathers: At one point during our day together, I asked him where his family members get their pills from. He raised his eyebrows at me and then said in a Big-Brother-might-be-listening kind of whisper that we were in territory that could get me called into the office, and it wouldnt be the first time. Still, he says he is prepared to deal with the consequences of being honest.

Whats more, Sinclair says he has nothing to do with the supplement industry, a claim that is mostly true. All of the companies he has started are working on creating FDA-approved drugs, not supplements. True, years ago he did work as a paid adviser to a resveratrol supplement company, Shaklee, though Sinclair says he cut off that relationship when the company started using his name for marketing.

Even if Sinclair isnt directly profiting when people buy supplements after hearing him speak, he may still be benefiting financially from talking about what he takes. Think about what the optics would be if someone says, Ive got this great potential therapeutic intervention, and then says theyre not taking it. Suddenly you are putting up red flags about your own science, Olshansky, the Illinois professor, says. So I can see why somebody who has a financial interest in a molecule would take it and brag about it. If it helps them get more money to do research, that may be one of the reasons they do it. Sierra, for his part, admits that as much as he dislikes when Sinclair shares what he is taking, it is probably good for commercial purposes.

Whether or not his personal habits have helped Sinclairs bottom line, theres no doubt hes raised a ton of funding and used it to start a slew of companies. Seven of them fall under the umbrella of Life Biosciences, a Boston holding company he cofounded with Australian investor Tristan Edwards with the goal of building clinical-stage biotech companies by harnessing the best science in the aging field. Edwards had been interested in the longevity space and searched for a scientist to work with. He had a call with Sinclair and was so convinced by what he heard that before he got off the phone, he had already booked a flight to Boston. The firm raised $25 million while in stealth mode in 2017 and has since raised $500 million more.

Another company, MetroBiotech (which falls under the holding company EdenRoc Sciences), is pursuing drugs inspired by the NAD+ booster NMN. Thats the one we were on our way to visit when Sinclairs Tesla tried to kill us. Upon our arrival, two men looking slightly disheveled and both wearing Hawaiian shirts greeted us; these were the organic chemists tasked with developing molecules that may one day become an FDA-approved drug. As they took me back to their lab, I noticed the paunch on one of them, the wrinkles on the other, and the fact that what little hair either of them had left on their heads was somewhere between gray and white. I lowered my voice and asked, So are you guys, you know, taking the stuff?

Of course not. We are scientists! one of them exclaimed, looking at me like I was the mad scientist in the room.

It doesnt take a PhD to know that the fact that two guys who arent taking NMN look old proves absolutely nothing. But it did make me feel a little more hopeful to learn that they were not. And the funny thing is that later in the day, when I asked Sinclair why he takes unapproved drugs knowing that there could be risks (and how much it pisses people off), he said the very same thing: I take them because I am a scientist.

Then, in total deadpan, he gave me another reason.

And because I would like to outlive my enemies.

David Sinclair with his wife, Sandra Luikenhuis, at the Time 100 party after the publication named him one of the worlds most influential people in 2014. / Getty Images

Sinclair and I were supposed to be at the gym at 5 p.m. to meet up with his 12-year-old son, Ben, and his about-to-be-80-year-old father. Because we were running late, he asked his wife to send his gym clothes with his dad. When we arrived, Sinclair came out of the locker room in his dress shoes. His wife, despite taking NMN herself, had forgotten to send his sneakers. Luckily, the trainer had an extra pair, and the Sinclair family got down to business.

First up were dead lifts. Ben had a go and did pretty well for a kid his age. Then Sinclair went. He started to wince midway into the second set but made it through. Finally, his father had his turn, dead-lifting 95 and then 115 pounds like it was nothing. The trainer told me most of his 80-year-old clients are working on maintaining their balance and lifting themselves out of chairs. Sinclairs dad is killing it in the gym. Well, I suppose the only thing this proves is how useless I am, Sinclair told me, frowning.

Of course, he is hoping it means something else. His father has been taking NMN for two years, and since starting, Sinclair said, it has changed his life, his attitude, and his energy levels. It has returned to him his joie de vivre.

When I asked Sinclairs dad directly how the pills are going for him, I realized that Sinclair definitely did not get his salesmanship skills from his father. Cant tell, he told me flatly, with a shrug. But all my friends are dying or going downhill and Im not.

Not only are Sinclairs dad and wife taking NMN, but so are his two dogs. His younger brother grew gray hairs and developed wrinkles before he accused Sinclair of using him as a negative control in his little family experiment. Sinclair admits the thought did cross his mind, but blood is thicker than science, and now his brother is on the regimen, too. Even several of his graduate students are taking some of the pills. When the postmenopausal mother of one of those grad students also began taking it, she started menstruating again. (Perhaps unsurprisingly, Sinclair has a fertility company, too.)

There was one person who never got the chance to take NMN, however, and it seems to haunt Sinclair. His mother was diagnosed with lung cancer at age 50 and had a lung removed. She managed to live another 20 years with one lung, which Sinclair says he would like to think had something to do with the fact that she took resveratrol. At the end of her life, when she took a turn for the worse, Sinclair packed some NMN in his suitcase and boarded a flight to Australia. When he got there, she started doing so much better that the doctors took her off her respirator, and she never took the NMN. She died unexpectedly 12 hours later. I thought the NMN would save her, he admits. Wouldnt anybody do whatever they can to try to save their mother?

As their workout wore on, Sinclairs son Ben had something he wanted to tell me. He wanted me to know that he would like to continue his fathers work if he ever dies. I was distracted from the tenderness of this statement by the presence of a single preposition.

If? I asked.

He may never die, he said.

I shrugged and smiled, but inside I was thinking that if he isnt joking, someone is in for a real shocker. Earlier in the day, Sinclair told me he was such a straight-talker that he had ruined the illusion of Santa Claus for his childrenand yet here his son could be thinking his father might never die. Such is life in the Sinclair household.

Still, not everyone in the family wants to see people live forever. Sinclairs oldest daughter doesnt agree with his work and has zero qualms about letting her dad know it. She has asked him why, when previous generations have screwed up this planet so royally, he thinks its a good idea to have the people who did the damage hang around any longer. She is not the only one. Emory University bioethicist Paul Root Wolpe, for instance, has called the longevity field a narcissistic quest and points out that generational shifts are necessary for innovation, progress, and social change.

As if in response, Sinclairs book has an end section in which he delves into many ways to fix the world he wants to create. There is, he argues, a solution to everything in a reality where people live to 150overpopulation, inequality, natural-resource limitationsif you are as hopeful as he is. Just as I was finishing up this piece, in fact, scientists published a study linking optimism to longevitymeaning Sinclair could stand to add even more years to his life. Indeed, if I squint hard enough, I can practically see him growing younger before my very eyes.

More here:
Has Harvard's David Sinclair Found the Fountain of Youth?